INNOVENTRIC
Ness Ziona
About INNOVENTRIC
Innoventric is a Structural Heart medical device company, mainly engaged in the development of percutaneous solutions for Tricuspid Regurgitation and right heart disease. Innoventric, a start-up company from Ness-Ziona, Israel, develops the unique Trillium™ technology for the treatment of Tricuspid Valve Regurgitation. The company was founded in 2017, and has rapidly progressed. Innoventric has performed over 10 implantations of the promising Trillium™ technology as part of its European first in human clinical trial. The company holds a broad patent portfolio for the Trillium™ and additional Tricuspid technologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $48.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2024)
- Website: innoventric.com
- Phone: [email protected]
Industries & Categories
Clinical Trials, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/innoventric-84059 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.